Impact of COVID-19 pandemic on the course of refractory chronic spontaneous urticaria under omalizumab treatment Müge Olgaç, Osman Ozan Yeğit, Şengül Beyaz, Nida Öztop, Can Tüzer, Deniz Eyice, Pelin Karadağ, Raif Coşkun, Semra Demir, Bahaauddin Çolakoğlu, Suna Büyüköztürk, Aslı Gelincik

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes? Emek Kocatürk, Emel Bülbül Başkan, Özlem Su Küçük, Mustafa Özdemir, Sinem Örnek, Pelin Kuteyla Can, Eda Haşal, Burhan Engin, Nilgün Atakan, Erkan Alpsoy

Urticaria and angioedema as possible reactions of omalizumab* Ozlem Ozbagcivan, Sevgi Akarsu, Turna Ilknur, Emel Fetil